Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2020-03-30 Annual Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
20-F
Annual Report FY 2019
2020-03-30 English
6-K
Foreign Filer Report
2020-03-26 English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Director's Dealing Classification · 100% confidence The document is a formal notification of transactions in company shares and linked securities (Restricted Stock Units and Warrants) by managerial employees (Board members and executives). It explicitly cites Article 19 of Regulation No. 596/2014 on Market Abuse, which is the standard regulatory framework for reporting insider/director dealings. This fits the definition of 'Director's Dealing' (DIRS).
2020-03-26 English
Director's Dealing 2020
Director's Dealing Classification · 100% confidence The document is titled "Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons" and explicitly states it discloses transactions made by managerial employees in accordance with Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This directly relates to insider trading or director/managerial dealings. The filing category 'Director's Dealing (DIRS)' covers reports of personal share transactions by company directors and executives. Although the document itself is a company announcement, the core subject matter is the disclosure of insider transactions, making DIRS the most specific fit, rather than the general 'RNS' or 'RPA' fallback, as DIRS is a defined category for this specific content type.
2020-03-26 English
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Director's Dealing Classification · 98% confidence The document explicitly states it is a 'Company Announcement' disclosing 'data of the transactions made in Genmab A/S by managerial employees and their closely associated persons' in accordance with Article 19 of Regulation No. 596/2014 (Market Abuse Regulation). This regulation mandates the disclosure of insider transactions by management. The filing category that specifically covers reports of personal share transactions by company directors and executives (insider trades) is 'Director's Dealing' (DIRS). Although the document mentions an 'Attachment' which likely contains the detailed transaction data, the announcement itself serves as the official notification of insider dealing.
2020-03-26 English
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and a New Member of Management, and Grant of Restricted Stock Units an
AGM Information Classification · 98% confidence The document explicitly states it is a 'Company Announcement' released immediately following the 'Annual General Meeting held on March 26, 2020'. The content details the constitution of the Board of Directors (appointment of Chairman/Deputy Chairman) and the subsequent grant of restricted stock units (RSUs) and warrants to management and employees. This content directly relates to the governance and immediate post-meeting actions following the AGM. While it mentions the AGM, the primary focus is on the board constitution and compensation/incentive grants resulting from the meeting's mandate, which aligns closely with AGM-related outcomes. However, the core subject matter—the appointment of directors and the granting of stock/warrants—is highly specific. Since the document is an announcement *following* the AGM and details board structure changes and remuneration/incentive grants, it strongly relates to AGM outcomes and governance. Given the options, 'AGM-R' (AGM Information) is the most appropriate fit as it covers materials shared during or immediately following the AGM, especially concerning board composition and related decisions. It is not a DEF 14A (Remuneration Report) as it's an announcement of grants, not the full remuneration policy details, nor is it a general MANG announcement as it is explicitly tied to the AGM outcome.
2020-03-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.